Delhi HC allows Dr. Reddy’s to export weight-loss drug semaglutide, calls Novo Nordisk’s case ‘weak’

The Delhi High Court declined to stay a single-judge order allowing Dr. Reddy's to export its semaglutide, observing Novo Nordisk's appeal presented a weak case. This decision permits Dr. Reddy's to supply the drug to countries without Novo Nordisk's patent protection, while the broader legal dispute over intellectual property continues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zfiOv8p
via IFTTT